PTC Therapeutics to Participate at Upcoming Investor Conferences
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
SOUTH PLAINFIELD, N.J., Feb. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present at the following conferences:
Cowen 40th Annual Health Care Conference Wednesday, March 4th at 10:40 a.m. ET
Barclays Global Healthcare Conference Tuesday, March 10th at 11:45 a.m. ET
The presentations will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation is available at the same website location.
About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
FOR MORE INFORMATION PLEASE CONTACT: | |
Media: | Investors: |
Jane Baj | Alex Kane |
+1 (908) 912-9167 | +1 (908) 912-9643 |
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-301011112.html
SOURCE PTC Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenant Inc. and TractIQ Partner to Bring Competitive Intelligence to Self Storage Operators
- Samsonite Group S.A. to Acquire BÉIS, Expanding its Lifestyle Portfolio and Enhancing Digital Capabilities
- Lithium Ionic Announces Agreement to Sell its Salinas Group of Lithium Properties to PLS for US$37.5 Million in Cash, Retaining a 2.0% Royalty on Future Spodumene Sales
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Barclays, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share